Atomo Diagnostics Limited (ASX:AT1)

Market Cap	29.98M +160.5%
Revenue (ttm)	3.79M -7.2%
Net Income	-4.97M
EPS	-0.01
Shares Out	810.18M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,282,641
Average Volume	2,130,472
Open	0.0380
Previous Close	0.0390
Day's Range	0.0370 - 0.0380
52-Week Range	0.0140 - 0.0480
Beta	1.19
RSI	45.43
Earnings Date	Jan 27, 2026

About Atomo Diagnostics

Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2010
• Employees: 85
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: AT1

Financial Performance

In fiscal year 2025, Atomo Diagnostics's revenue was 3.79 million, a decrease of -7.20% compared to the previous year's 4.09 million. Losses were -4.97 million, -27.41% less than in 2024.